Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (570)	2/15/1999 7:17:00 AM
From: Jongmans	Read Replies (1) \| Respond to of 1073

We have to realise that, due to the,in general, biotech-adverse attitude of investors shareprices in this sector are so squeezed, that the market-capitalisation makes them again interesting objectives for venture-capital investors/cq give large pharmaceutical companies access to new productlines at a large discount to comparable investing in their own research. I have the impression that at,least partly ,these convertible-financings (floorless or not) in the biotech-sector are done by venture-capitalists (with a longer term interest in this neglected sector!?!?). In fact it are investors in general, that opened the possibility to these financers to get hold of bundles of shares in interesting companies at bottomed out prices.Who's responsability? Martin